Delivery Order SPE2DB24D3013-SPE2DB25FFNRP
- Not listed
- The Defense Logistics Agency awarded a $5,322.00 delivery order to AmerisourceBergen Drug Corp for Miebo 100% eye drop (3ml) on September 3, 2025, with completion by September 4, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement needs, particularly supporting...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,897.98 for Miebo 100% eye drop (3mL) under a firm fixed price contract. The award was made on September 5, 2025, with an ultimate completion date of September 8, 2025. This non-set-aside delivery order represents a competitive award to the pharmaceutical distributor for pharmaceutical supply to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $5,957.57 to AmerisourceBergen Drug Corp for MIEBO 100% eye drop solution (3ml) on August 7, 2025, with an ultimate completion date of August 8, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,072.18 to AmerisourceBergen Drug Corp for MIEBO 100% eye drop solution (3ml) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a firm fixed-price contract with no set-aside designation, performed at the contractor's Conshohocken, Pennsylvania location. The award represents a small-value delivery order under the company's larger pharmaceutical supply vehicle with DLA. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,448.13 to AmerisourceBergen Drug Corp for MIEBO 100% Eye Drop (3ml) on August 25, 2025, with an ultimate completion date of August 26, 2025. This is a firm fixed price delivery order with no set-aside designation, to be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a competitively awarded transaction under AmerisourceBergen's existing federal contract portfolio...
- The Defense Logistics Agency awarded a $11,297.46 delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Miebo 100% eye drop (3ml units). The contract, which carries a firm fixed price structure with no set-aside designation, is scheduled for completion by June 9, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $9,567.86 delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Miebo 100% eye drop medication in 3 milliliter units. This is a firm fixed price contract with no set-aside designation, reflecting open competition based on AmerisourceBergen's demonstrated capability to meet federal procurement requirements. The contract is set for ultimate completion on September 11, 2025, and will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Miebo 100% eye drop solution in 3ml quantities. The contract carries a ceiling value of $23,965.92 and represents a firm fixed-price delivery order with an ultimate completion date of August 15, 2025. This award is a non-set-aside contract, meaning it was competitively awarded and available to all eligible vendors. The performance location is AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $7,830.29 to AmerisourceBergen Drug Corp for MIEBO 100% Eye Drop 3ML on August 25, 2025, with an ultimate completion date of August 26, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The product will be delivered to the company's place of performance in Conshohocken, PA. This delivery order represents a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Miebo 100% eye drop medication in 3 mL units. This competitively awarded, non-set-aside contract carries a ceiling value of $2,325.38 with a firm fixed price structure and an ultimate completion date of August 5, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The order represents...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFNRPDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,845.23 to AmerisourceBergen Drug Corp for the supply of Miebo 100% eye drop in 3ml quantities. The contract is a firm fixed price delivery order with an ultimate completion date of July 25, 2025, and was awarded on July 24, 2025, with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen has demonstrated its capability to meet DLA requirements through open competition across numerous contract awards encompassing specialty medications, vaccines, and medical devices across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 7/24/25 |